Inside Spark Therapeutics' Investigational SPK-8011 For Hemophilia A With Dr. Tiffany Chang

Source: Cell & Gene

Spark Therapeutics' Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company's data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease.